+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cutaneous Leishmaniasis Drugs by Product Type, by Distribution Channel, by Geographic Scope And Forecast

  • ID: 5301356
  • Report
  • August 2020
  • Region: Global
  • 102 pages
  • Verified Market Research

FEATURED COMPANIES

  • Gland Pharma
  • GloxoSmithKline
  • Knight Therapeutics
  • Novartis
  • Pfizer
  • Sanofi
Cutaneous Leishmaniasis Drugs Market Size And Forecast

According to the publisher, the Global Cutaneous Leishmaniasis Drugs market was valued at USD 40.5 Million in 2018 and is projected to reach USD 56.1 Million by 2026, growing at a CAGR of 4.23% from 2019 to 2026.

Global Cutaneous Leishmaniasis Drugs Market Outlook

About 95% of cutaneous leishmaniasis cases occur in the Americas, the Mediterranean Basin, the Middle East, and Central Asia. In 2017 over 95% of new cutaneous leishmaniasis cases occurred in six countries: Brazil, Colombia, Afghanistan, Algeria, Iran, Iraq, and the Syrian Arab Republic. According to the World Health Organization, it is anticipated that between 600 000 to 1 million new cases arise worldwide yearly.

Global Cutaneous Leishmaniasis Drugs Market: Segmentation Analysis

The Global Cutaneous Leishmaniasis Drugs market is segmented on the basis of product type, distribution channel, and geography.

Global Cutaneous Leishmaniasis Drugs Market Competitive Landscape

The “Global Cutaneous Leishmaniasis Drugs Market” study report will provide valuable insight with an emphasis on global market including some of the major players such as Knight Therapeutics, Gland Pharma, Sanofi, Novartis, GloxoSmithKline, Pfizer, Cheplapharm Arzneimittel GmbH and Jassen Pharmaceutical.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Gland Pharma
  • GloxoSmithKline
  • Knight Therapeutics
  • Novartis
  • Pfizer
  • Sanofi
1 Introduction
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Assumptions
1.5 Limitations

2 Research Methodology
2.1 Data Mining
2.2 Secondary Research
2.3 Primary Research
2.4 Subject Matter Expert Advice
2.5 Quality Check
2.6 Final Review
2.7 Data Triangulation
2.8 Bottom-Up Approach
2.9 Top Down Approach
2.1 Research Flow
2.11 Data Sources

3 Executive Summary
3.1 Market Overview
3.2 Global Cutaneous Leishmaniasis Drugs Market Geographical Analysis (Cagr %)
3.3 Global Cutaneous Leishmaniasis Drugs Market, by Product Type (Usd Thousand)
3.4 Global Cutaneous Leishmaniasis Drugs Market, by Distribution Channel (Usd Thousand)
3.5 Future Market Opportunities
3.6 Global Market Split

4 Market Outlook
4.1 Global Cutaneous Leishmaniasis Drugs Market Outlook
4.2 Market Drivers
4.2.1 Increasing Healthcare Spending
4.3 Market Restraints
4.3.1 Global and Country-Level Barriers to An Effective Supply of Leishmaniasis Medicines and Diagnostics
4.4 Market Opportunities
4.4.1 Potential for a New Line of Treatment
4.5 Market Challenges
4.5.1 Presence of Falsified Leishmaniasis Drugs
4.6 First-Line Drugs, Patents, Clinical Trials & Compounds Currently Under Pipeline
4.6.1 First-Line Drugs
4.6.2 Patents
4.6.3 Clinical Trials
4.6.4 Compounds Currently Under Pipeline

5 Market, by Product Type
5.1 Overview
5.2 Pentavalent Antimonials
5.3 Antifungal Drugs
5.4 Anti-Leishmanial/Antimicrobial Drugs

6 Market, by Distribution Channel
6.1 Overview
6.2 Hospitals Pharmacies
6.3 Retail Pharmacies
6.4 Online Pharmacies

7 Market, by Geography
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 France
7.3.3 U.K.
7.3.4 Rest of Europe
7.4 Asia-Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Rest of Asia-Pacific
7.5 Row
7.5.1 Middle East & Africa
7.5.2 Latin America

8 Competitive Landscape
8.1 Overview
8.2 Company Ranking Analysis

9 Company Profiles
9.1 GlaxoSmithKline plc.
9.1.1 Company Overview
9.1.2 Company Insights
9.1.3 Segment Breakdown
9.1.4 Product Benchmarking
9.1.5 Key Development
9.1.6 SWOT Analysis
9.1 Knight Therapeutics Inc.
9.1.1 Company Overview
9.1.2 Company Insights
9.1.3 Product Benchmarking
9.1.4 SWOT Analysis
9.2 Sanofi
9.2.1 Company Overview
9.2.2 Company Insights
9.2.3 Segment Breakdown
9.2.4 Product Benchmarking
9.2.5 SWOT Analysis
9.3 Novartis AG
9.3.1 Company Overview
9.3.2 Company Insights
9.3.3 Segment Breakdown
9.3.4 Product Benchmarking
9.4 Pfizer Inc.
9.4.1 Company Overview
9.4.2 Company Insights
9.4.3 Segment Breakdown
9.4.4 Product Benchmarking
9.5 Janssen Pharmaceuticals, Inc.
9.5.1 Company Overview
9.5.2 Company Insights
9.5.3 Segment Breakdown
9.5.4 Product Benchmarking
9.6 Cheplapharm Arzneimittel GmbH
9.6.1 Company Overview
9.6.2 Company Insights
9.6.3 Product Benchmarking
9.7 Gland Pharma Limited
9.7.1 Company Overview
9.7.2 Product Benchmarking
Note: Product cover images may vary from those shown
  • Knight Therapeutics
  • Gland Pharma
  • Sanofi
  • Novartis
  • GloxoSmithKline
  • Pfizer
  • Cheplapharm Arzneimittel GmbH and Jassen Pharmaceutical
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll